Cost-Effectiveness Studies in HIV Treatment with Lopinavir/Ritonavir: A Review:

Global & Regional Health Technology Assessment

PaolaCodella¹ 

关键词: Antiretroviral therapy;    Cost effectiveness;    HIV;    Lopinavir/ritonavir;   

DOI  :  10.5301/GRHTA.5000184

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

In the last 20 years the spread of antiretroviral drugs has significantly improved the life expectancy of people with HIV. Nevertheless, antiretroviral therapy comes with an increase in expenditure and prescription because often the combination of two or more active ingredients is used. Recent studies have shown that ritonavir-boosted protease inhibitors – the class of antiviral drugs lopinavir/ritonavir belong to – show the same effectiveness as the combination of antiretroviral therapy (cART) and reduce both the cost of treatment and the occurrence of the side effects associated with long-term exposure to combinations of drugs. In this paper we conducted a systematic review of the evidence about the cost-effectiveness of lopinavir/ritonavir (LPV/r). In particular, we used as search engine: PubMed and Dare. In PubMed search, we used the following key words: HIV, Kaletra, lopinavir/ritonavir, cost effectiveness, cost minimization, cost utility, cost of illness, cost benefit, economic evaluation, economic assessment, economic analysis. In the DARE database we used as keywords: lopinavir/ritonavir and Kaletra. The PubMed search yielded 299 articles, while Dare yielded ten.

【 授权许可】

CC BY